Trial result ·
Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This trial tested a milder transplant plan. It enrolled children and young people with sickle cell disease. Each got donor cells from a sibling with the same HLA type. The plan used alemtuzumab, radiation and sirolimus. It ran at many centers. Ages ran from 2.9 to 21.9 years, with a median of 13.5.
What they found
Donor cells took hold at first in all of the children. Later, 7 children had secondary graft failure. Everyone was alive at 2 years. No child developed acute or chronic graft-versus-host disease. Quality of life was stable early and then rose at 1 year. After year 2, 3 more children had a second transplant.
What it means for patients
The authors say changes are needed to cut graft failure. They say this plan offers a relatively low-toxicity option. It is for children with an identical sibling donor.
Why it is not certain yet
The trial had no comparison group. Graft failure was a real problem for 7 children. It was tested only in children with a sibling donor of the same HLA type. The abstract gives no data past year 2.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study.
PubMed · PMID 41945757We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Sickle cell disease publications